Cutaneous gangrene of the arms and legs after cardiopulmonary resuscitation: A rare presentation of catastrophic antiphospholipid syndrome

American Journal of Emergency Medicine

Volumn 35, Issue 1, 2017, Pages 191.e3-191.e5

  Deng, Shuixiang ^a   Shen, Jun ^a   Ni, Jie ^a   Gong, Ye ^a   Zhu, Hechen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; APIXABAN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CREATININE; D DIMER; DOPAMINE; HEMOGLOBIN; HEPARIN; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; POTASSIUM; PREDNISOLONE; ANTICOAGULANT AGENT; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BACKACHE; BELOW KNEE AMPUTATION; BLOOD TRANSFUSION; CASE REPORT; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CONTINUOUS RENAL REPLACEMENT THERAPY; CONVALESCENCE; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FAINTNESS; FEVER; FINGER AMPUTATION; GANGRENE; HEART VENTRICLE FIBRILLATION; HEPARINIZATION; HUMAN; HYPERKALEMIA; HYPERTRANSAMINASEMIA; IMMUNOTHERAPY; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; MAINTENANCE DRUG DOSE; MALE; MIDDLE AGED; OLIGURIA; OXYGEN SATURATION; PARESTHESIA; PARTIAL THROMBOPLASTIN TIME; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RESUSCITATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; COMPLICATION; FOOT DERMATOSES; HAND DERMATOSES; PATHOLOGY; RENAL REPLACEMENT THERAPY; SKIN; SYNCOPE; TERMINAL DISEASE; VENTRICULAR FIBRILLATION;

ACUTE KIDNEY INJURY; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CARDIOPULMONARY RESUSCITATION; CATASTROPHIC ILLNESS; FEVER; FOOT DERMATOSES; GANGRENE; GLUCOCORTICOIDS; HAND DERMATOSES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; OLIGURIA; PREDNISOLONE; RENAL REPLACEMENT THERAPY; SKIN; SYNCOPE; VENTRICULAR FIBRILLATION;

EID: 85004092997     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2016.06.086     Document Type: Article

References (12)

1. [1] Miyakis, S, Lockshin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:2 (2006), 295–306.
2. [2] Asherson, RA, The catastrophic antiphospholipid syndrome. J Rheumatol 19:4 (1992), 508–512.
3. [3] Kazzaz, NM, McCune, WJ, Knight, JS, Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol 28:3 (2016), 218–227.
4. [4] Asherson, RA, Piette, JC, The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus 5:5 (1996), 414–417.
5. [5] Asherson, RA, Cervera, R, de Groot, PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:7 (2003), 530–534.
6. [6] Cervera, R, Font, J, Gomez-Puerta, JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64 (2005), 1205–1209.
7. [7] Nayer, A, Ortega, LM, Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol 3:1 (2014), 9–17.
8. [8] Cervera, R, Bucciarelli, S, Plasín, MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS registry”. J Autoimmun 32:3–4 (2009), 240–245.
9. [9] Cervera, R, Rodriguez-Pinto, I, Colafrancesco, S, et al. 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev 13:7 (2014), 699–707.
10. [10] Bucciarelli, S, Espinosa, G, Cervera, R, et al. Mortality in catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54:8 (2006), 2568–2576.
11. [11] Erkan, D, Aguiar, CL, Andrade, D, et al. 14th international congress on antiphospholipid antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13:6 (2014), 685–696.
12. [12] Bucciarelli, S, Erkan, D, Espinosa, G, et al. Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin Rev Allergy Immunol 36:2–3 (2009), 80–84.